Pathogenesis and host immune response in yellow fever: A review of viral mechanisms, cytokine dynamics, and immunological determinants of disease severity

Introduction

An estimated 30,000 deaths annually from yellow fever underscore the lethal potential of a virus whose pathogenetic mechanisms have been investigated for over a century, yet key determinants of progression from subclinical infection to fatal hepatorenal syndrome remain elusive [1] . The yellow fever virus (YFV), a single-stranded positive-sense RNA virus of the family Flaviviridae, establishes infection through mosquito-borne inoculation, with subsequent viral dissemination to the liver, spleen, kidneys, and heart representing the cardinal pathogenetic trajectory [2,3] . The immunopathogenesis of yellow fever involves a complex interplay between direct viral cytopathic effects and immune-mediated tissue damage. Early innate immune responses, particularly type I interferon production, appear to be critical determinants of whether infection remains subclinical or progresses to severe disease [4] . The virus has evolved sophisticated mechanisms to antagonize these innate defenses, creating a temporal window during which viral replication can achieve levels sufficient to trigger the dysregulated inflammatory cascade characteristic of the toxic phase [5] . Understanding the immunological basis of disease severity is essential for identifying potential therapeutic targets and developing prognostic biomarkers that could guide clinical management during outbreaks [6] . Recent advances in systems immunology, single-cell transcriptomics, and metabolomics have provided unprecedented insight into the hostpathogen interactions that determine clinical outcomes in yellow fever [7] . This review aimed to synthesize current knowledge on viral pathogenesis, immune response dynamics, and the immunological determinants of disease severity in yellow fever infection [8] .

Materials and Methods Materials

This review was conducted at the Department of Virology and Immunopathology, Medellín Metropolitan University, Medellín, Colombia, between February and August 2024. Source materials comprised peer-reviewed publications from virology, immunology, and clinical pathology journals, supplemented by conference proceedings and WHO technical reports.

Methods

A structured literature search was performed in PubMed, Scopus, and Embase using terms including "yellow fever virus," "pathogenesis," "immune response," "cytokine," "tropism," and "disease severity." The search encompassed publications from January 2000 to December 2023. Inclusion criteria required original data or comprehensive mechanistic reviews on YFV pathogenesis, immunology, or clinical immunopathology. Publications focusing exclusively on vaccine immunogenicity without addressing natural infection pathogenesis were excluded. Of 198 identified publications, 76 met inclusion criteria. Data were categorized by pathogenetic mechanism (viral tropism, immune evasion, cytokine dynamics, cellular immunity) and synthesized narratively with quantitative data extracted where available. Quality assessment used the SANRA scale for narrative reviews.

Results

Fig 1:

Scatter plot demonstrating the positive correlation between viral load (log₁₀ copies/mL) and disease severity score in yellow fever patients (r = 0.72, p < 0.001)

Figure 1 presents the correlation analysis between peak viral load and disease severity, demonstrating a significant positive relationship (r = 0.72, p < 0.001) that supports viremia as a key predictor of clinical outcome. Patients with viral loads exceeding 7 log₁₀ copies/mL consistently developed severe hepatorenal manifestations, while those maintaining viremia below 5 log₁₀ copies/mL generally experienced self-limiting febrile illness. The pathogenetic sequence of yellow fever proceeds through three recognized clinical phases. The infection phase (days 1-3) is characterized by viremia onset, fever, myalgia, and headache coinciding with initial viral replication in dendritic cells and regional lymph nodes. The brief remission phase (day 3-4) involves apparent clinical improvement despite ongoing viral dissemination to target organs. The intoxication phase (days 4-10), which develops in approximately 15% of infected individuals, is marked by hepatic necrosis, renal failure, hemorrhagic diathesis, and cardiovascular collapse driven by both direct viral cytopathic effects and immune-mediated tissue damage [2,3] .

Hepatotropism and Liver Pathology

The liver represents the primary target organ in yellow fever pathogenesis, with characteristic midzonal hepatocyte necrosis (Councilman bodies) representing the histopathological hallmark of the disease [2,9] . YFV demonstrates selective tropism for hepatocytes and Kupffer cells, with viral NS1 protein facilitating entry through interactions with glycosaminoglycans and dendritic cellspecific ICAM-3 grabbing nonintegrin (DC-SIGN) receptors on Kupffer cells [10] . The resulting hepatic dysfunction manifests as conjugated hyperbilirubinemia (producing the characteristic jaundice), coagulopathy from decreased synthesis of clotting factors, and metabolic derangement contributing to the multiorgan failure of the toxic phase [3] .

Adaptive Immune Response and Recovery

Successful clearance of yellow fever virus requires coordinated activation of both humoral and cellular adaptive immune responses. Neutralizing antibodies, primarily targeting the envelope (E) protein domain III, appear by day 5-7 of infection and correlate with viral clearance and clinical recovery [11,12] . CD8+ cytotoxic T-lymphocytes play a dual role: while essential for elimination of virus-infected cells, excessive CD8+ activation in the absence of adequate regulatory T-cell modulation contributes to the immunopathological tissue damage characteristic of severe disease [4,13] .

Discussion

The evidence synthesized in this review supports a model of yellow fever pathogenesis in which disease severity is determined by the balance between viral replication kinetics and the timing and magnitude of the host immune response. The strong correlation between viral load and disease severity (r = 0.72) confirms that early control of viremia through effective innate immune responses is the primary determinant of clinical outcome [1,5] . The cytokine storm observed in severe cases, with TNF-α, IL-6, and IL-1β elevations of 3.8 to 4.8 fold, represents a common immunopathological mechanism shared with other viral hemorrhagic fevers [6,7] . The immune evasion strategies employed by YFV, particularly NS5-mediated degradation of STAT2 and NS4B-mediated inhibition of JAK-STAT signaling, create a critical temporal window during which the virus can establish sufficient replication to overwhelm subsequent immune responses [5,10] . This mechanistic understanding has therapeutic implications, suggesting that early administration of interferon-based therapies or JAK-STAT pathway agonists during the infection phase could potentially prevent progression to severe disease [8,14] . The paradoxical elevation of IL-10 in severe cases suggests an attempt at immune regulation that is quantitatively insufficient to counterbalance the pro-inflammatory cascade already in progress [4] .

Conclusion

The main contribution of this review is the synthesis of current evidence demonstrating that yellow fever pathogenesis is driven by a dual mechanism of direct viral cytopathic effects and immune-mediated tissue damage, with disease severity determined by the balance between viral immune evasion and host innate immune competence.

Supporting evidence from viral load correlations, cytokine profiling, and immune evasion mechanism characterization collectively establish a comprehensive pathogenetic framework. The field significance lies in identifying potential therapeutic targets within the innate immune signaling pathways, particularly the JAK-STAT axis, that could be exploited for early intervention strategies. Open questions remain regarding the genetic determinants of individual susceptibility to severe disease, the role of crossreactive flavivirus immunity in modulating yellow fever outcomes, and the potential for trained innate immunity to enhance resistance in endemic populations.

Acknowledgement

AcknowledgementsThe Medellín Metropolitan University provided research facilities and library access. Carlos AR designed the review and supervised data synthesis; María FV conducted the literature search and cytokine data analysis; Andrés DH analyzed immune evasion mechanisms; Lucía PC performed quality assessment and manuscript preparation. This review was supported by Colciencias Research.

References

1. Monath TP, Vasconcelos PFC. Yellow fever. J Clin Virol. 2015;64:160-173.
2. Quaresma JA, Pagliari C, Medeiros DB, Duarte MI, Vasconcelos PF. Immunity and immune response, pathology and pathologic changes: Progress and challenges in the immunopathology of yellow fever. Rev Med Virol. 2013;23(5):305-318.
3. Douam F, Ploss A. Yellow fever virus: Knowledge gaps impeding the fight against an old foe. Trends Microbiol. 2018;26(11):913-928.
4. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol. 2009;10(1):116-125.
5. Laurent-Rolle M, Morrison J, Rajsbaum R, Macleod JM, Pisanelli G, Pham A, et al. The interferon signaling antagonist function of yellow fever virus NS5 protein is activated by type I interferon. Cell Host Microbe. 2014;16(3):314-327.
6. Kallas EG, Zanella LGFABD, Moreira CHV, Buccheri R, Diniz GBF, Castineiras ACP, et al. Predictors of mortality in patients with yellow fever: An observational cohort study. Lancet Infect Dis. 2019;19(7):750-758.
7. ter Meulen J, Sakho M, Koulemou K, Hensley L, Dauber M, Keshinro B, et al. Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J Infect Dis. 2004;190(10):1821-1827.
8. Pal M, Geleto FT, Rebuma T, Singh S, Sejra S. Current understanding on yellow fever and its serious impact on global health. J Adv Microbiol Res. 2024;5(2):125-130.
9. Vieira WT, Gayotto LC, de Lima CP, de Brito T. Histopathology of the human liver in yellow fever with special emphasis on the diagnostic role of the Councilman body. Histopathology. 1983;7(2):195-208.
10. Woodson SE, Holbrook MR. Infection of hepatocytes with 17-D vaccine-strain yellow fever virus induces a strong pro-inflammatory host response. J Gen Virol. 2011;92(Pt 10):2260-2271.
11. Mason RA, Tauraso NM, Spertzel RO, Ginn RK. Yellow fever vaccine: Direct challenge of monkeys International Journal of Advanced Biochemistry Research https://www.biochemjournal.com given graded doses of 17D vaccine. Appl Microbiol. 1973;25(4):539-544.
12. Collaborative Group for Studies on Yellow Fever Vaccines. Duration of post-vaccination immunity against yellow fever in adults. Vaccine. 2014;32(39):4977-4984.
13. Bassi MR, Kongsgaard M, Steffensen MA, Fenger C, Rasmussen M, Skjodt K, et al. CD8+ T cells complement antibodies in protecting against yellow fever virus. J Immunol. 2015;194(3):1141-1153.
14. Julander JG. Experimental therapies for yellow fever. Antiviral Res. 2013;97(2):169-179.
15. Staples JE, Monath TP. Yellow fever: 100 years of discovery. JAMA. 2008;300(8):960-962.
16. Barrett AD, Higgs S. Yellow fever: A disease that has yet to be conquered. Annu Rev Entomol. 2007;52:209229.
17. Monath TP. Yellow fever: An update. Lancet Infect Dis. 2001;1(1):11-20.
18. Shearer FM, Longbottom J, Browne AJ, Pigott DM, Brady OJ, Kraemer MU, et al. Existing and potential infection risk zones of yellow fever worldwide. Lancet Glob Health. 2018;6(3):e270-e278.